Jiang Zhong Pharmaceutical Co.,Ltd provided earning guidance for the quarter ended March 31, 2022. for the quarter, the company is expected to have a total operating income of approximately RMB 890 million, representing a year-on-year increase of approximately 30% and the net profit attributable to shareholders of the listed company is expected to be approximately RMB180 million, representing a year-on-year increase of approximately 11%.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
27.91 CNY | +1.01% | +2.38% | +33.67% |
Apr. 26 | Jiang Zhong Pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Mar. 25 | Jiang Zhong Pharmaceutical Co.,Ltd Proposes Cash Dividend | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+33.67% | 2.4B | |
+30.65% | 588B | |
-3.42% | 364B | |
+18.02% | 326B | |
+4.27% | 285B | |
+14.83% | 239B | |
+9.80% | 210B | |
-7.36% | 200B | |
+8.12% | 167B | |
-1.42% | 161B |
- Stock Market
- Equities
- 600750 Stock
- News Jiang Zhong Pharmaceutical Co.,Ltd
- Jiang Zhong Pharmaceutical Co.,Ltd Provides Earning Guidance for the Quarter Ended March 31, 2022